US4374127A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Herpes sub unit vaccine
Assignee: Merck and Co Inc
•
Filing: 1980-02-11
•
Granted: 1983-02-15
•
Expires: 2000-02-11
Abstract
Abstract Herpes virus subunit antigens suitable for vaccine use are prepared by (1) treating virus-infected cells with a surfactant and varying concentrations of salt to extract and solubilize viral-directed glycoproteins, (2) fractionating the solubilized material by chromatographic procedures to enrich the viral-directed glycoproteins and to remove unwanted proteins and nucleic acids, and (3) optionally treating the subunit antigens with deoxyribonuclease and formaldehyde to assure safety.
Inventors
- 👤 Vivian M. Larson
- 👤 E. Dale Lehman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 13:24
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/245; A61K2039/555; A61K2039/55505; C; C12; C12N; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16634
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
107 words
An antigenic, immunogenic HSV-2 subunit vaccine consisting essentially of 3 groups of viral directed membrane-bound glycoproteins which are soluble in the presence of a non-ionic or anionic surfactant, the first of the three groups being from about 110,000 to about 130,000 daltons, the second of the three groups being from about 83,000 to about 90,000 daltons, and the third of the three groups being from about 55,000 to about 60,000 daltons, the subunit vaccine being substantially free of intact DNA and being capable of inducing neutralizing antibody and of being administered as a vaccine at a protein use level of from about 1 to about 100 μg.
Claim 2
Dependent Claim
107 words
An antigenic, immunogenic HSV-2 subunit vaccine consisting essentially of 3 groups of viral directed membrane-bound glycoproteins which are soluble in the presence of a non-ionic or anionic surfactant, the first of the three groups being from about 110,000 to about 130,000 daltons, the second of the three groups being from about 83,000 to about 90,000 daltons, and the third of the three groups being from about 55,000 to about 60,000 daltons, the subunit vaccine being substantially free of intact DNA and being capable of inducing neutralizing antibody and of being administered as a vaccine at a protein use level of from about 1 to about 100 μg.
Claim 3
Dependent Claim
10 words
A vaccine according to claim 1 additionally containing a stabilizer.
Claim 4
Dependent Claim
10 words
A vaccine according to claim 1 additionally containing an adjuvant.
Claim 5
Dependent Claim
78 words
An antigenic, immunogenic HSV-1 subunit vaccine consisting essentially of two groups of viral directed membrane-bound glycoproteins which are soluble in the presence of a nonionic or anionic surfactant, the first group being about 123,000 daltons and the second group being about 60,000 daltons, the subunit being substantially free of intact DNA and being capable of inducing neutralizing antibody and of being administered as a vaccine at a protein use level of from about 1 to about 100 μg.
Claim 6
Dependent Claim
78 words
An antigenic, immunogenic HSV-1 subunit vaccine consisting essentially of two groups of viral directed membrane-bound glycoproteins which are soluble in the presence of a nonionic or anionic surfactant, the first group being about 123,000 daltons and the second group being about 60,000 daltons, the subunit being substantially free of intact DNA and being capable of inducing neutralizing antibody and of being administered as a vaccine at a protein use level of from about 1 to about 100 μg.
Claim 7
Dependent Claim
10 words
A vaccine according to claim 4 additionally containing a stabilizer.
Claim 8
Dependent Claim
10 words
A vaccine according to claim 4 additionally containing an adjuvant.
Claim 9
Dependent Claim
12 words
A vaccine comprising an antigen according to claim 1 adsorbed on alum.
Claim 10
Dependent Claim
12 words
A vaccine comprising an antigen according to claim 4 adsorbed on alum.
References Cited (Backward Citations)
FR2300M
Cited
GB1140316A
Cited
US3452135A
Cited
US3651213A
Cited
US3897549A
Cited
US4140762A
Cited
EP0001365A1
Cited
US4235877A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-02-14 | 1986-08-16 | 1987-02-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-02-14 | 1990-08-16 | 1991-02-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-02-14 | 1994-08-16 | 1995-02-15 | $7700.00 | Window Closed / Lapsed |